Dr. Grace Lee received her PhD in Chemistry at State University of New York at Binghamton. She did her postdoctoral training in atherosclerosis pathophysiology with Dr. Ira Tabas at Columbia University, followed by a 5-year stint in drug discovery research targeting cardiovascular and metabolic diseases. Dr. Lee joined the Hotamışlıgil lab in 2012. Her main interest is to identify novel therapeutic targets for the treatment of metabolic diseases as well as facilitating the streamlining of validated targets into drug discovery pipeline. Currently she is involved in the development of blocking antibodies for circulating FABP4.
